Melinta Therapeutics (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that it has received a commitment from Vatera Healthcare Partners LLC and its affiliates for a convertible loan facility in the amount of up to of $135 million, with the option to be converted into preferred shares … Continued
The post Melinta Therapeutics Announces Commitment for New Credit Facility of Up to $135 Million appeared first on Investing News Network.